首页 > 最新文献

Journal of the American College of Cardiology最新文献

英文 中文
Artificial Intelligence in Cardiovascular Clinical Trials 人工智能在心血管临床试验中的应用
IF 21.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-04 DOI: 10.1016/j.jacc.2024.08.069
Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial’s life cycle, including designing the trial, identifying eligible patients, obtaining informed consent, ascertaining physiological and clinical event outcomes, interpreting imaging, and analyzing or disseminating the results. Nevertheless, AI poses risks, including generating inaccurate results, amplifying biases against underrepresented groups, and violating patient privacy. Medical journals and regulators are developing new frameworks to evaluate AI research tools and the data they generate. Given the high-stakes role of randomized trials in medical decision making, AI must be integrated carefully and transparently to protect the validity of trial results.
随机临床试验是确定心血管疗法疗效和安全性的黄金标准。然而,目前的关键性试验成本高昂、时间漫长且不够多样化。新兴的人工智能(AI)技术有可能实现临床试验操作的自动化和简化。本综述介绍了在试验的整个生命周期中整合人工智能的机会,包括设计试验、确定符合条件的患者、获得知情同意、确定生理和临床事件结果、解释成像以及分析或传播结果。然而,人工智能也存在风险,包括产生不准确的结果、扩大对代表性不足群体的偏见以及侵犯患者隐私。医学期刊和监管机构正在开发新的框架,以评估人工智能研究工具及其生成的数据。鉴于随机试验在医疗决策中的重要作用,必须谨慎、透明地整合人工智能,以保护试验结果的有效性。
{"title":"Artificial Intelligence in Cardiovascular Clinical Trials","authors":"","doi":"10.1016/j.jacc.2024.08.069","DOIUrl":"10.1016/j.jacc.2024.08.069","url":null,"abstract":"<div><div>Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial’s life cycle, including designing the trial, identifying eligible patients, obtaining informed consent, ascertaining physiological and clinical event outcomes, interpreting imaging, and analyzing or disseminating the results. Nevertheless, AI poses risks, including generating inaccurate results, amplifying biases against underrepresented groups, and violating patient privacy. Medical journals and regulators are developing new frameworks to evaluate AI research tools and the data they generate. Given the high-stakes role of randomized trials in medical decision making, AI must be integrated carefully and transparently to protect the validity of trial results.</div></div>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":21.7,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142574672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertensive Disorders of Pregnancy Increase the Risk for Myocardial Infarction: A Population-Based Study. 妊娠期高血压疾病增加心肌梗死风险:一项基于人群的研究。
IF 21.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-02 DOI: 10.1016/j.jacc.2024.06.049
Lisa E Vaughan, Yoshihisa Kanaji, Sonja Suvakov, Santosh Parashuram, Yvonne S Butler Tobah, Alanna M Chamberlain, Suzette J Bielinski, Natasa Milic, Rajiv Gulati, Karl A Nath, Amir Lerman, Vesna D Garovic

Background: Angiographic evidence of the anatomy of coronary arteries and the type of coronary artery lesions in women with a history of hypertensive disorders of pregnancy (HDP) are poorly documented.

Objectives: This study sought to determine the role of a history of HDP as a unique risk factor for early coronary artery disease (CAD) and type of acute coronary syndrome (ACS) (ie, atherosclerotic vs myocardial infarction with nonobstructive coronary arteries [MINOCA]) in women who underwent coronary angiography.

Methods: This study used a population-based cohort of parous female patients with incident CAD who underwent coronary angiography and age-matched control subjects. The SYNTAX (Synergy between PCI [percutaneous coronary intervention] with TAXUS [Boston Scientific] and Cardiac Surgery) score was assessed to determine the complexity and degree of CAD; MINOCA was diagnosed in the presence of clinical acute myocardial infarction in the absence of obstructive coronary disease.

Results: A total of 506 parous female Olmsted County, Minnesota (USA) residents had incident CAD and angiographic data from November 7, 2002 to December 31, 2016. Women with HDP were younger than normotensive women at the time of the event (median: 64.8 years vs 71.8 years; P = 0.030). There was a strong association between HDP and ACS (unadjusted P = 0.018). Women with HDP compared with women with normotensive pregnancies were more likely to have a higher SYNTAX score (OR: 2.28; 95% CI: 1.02-5.12; P = 0.046), and MINOCA (OR: 2.08; 95% CI: 1.02-4.25; P = 0.044).

Conclusions: A history of HDP is associated with CAD earlier in life and with a future risk for myocardial infarction with both obstructive and nonobstructive coronary arteries. This study underscores the need for timely detection and treatment of nonobstructive disease, in addition to traditional risk factors.

背景:关于有妊娠高血压疾病(HDP)病史的妇女的冠状动脉解剖结构和冠状动脉病变类型的血管造影证据很少:本研究旨在确定在接受冠状动脉造影术的妇女中,HDP 病史作为早期冠状动脉疾病(CAD)和急性冠状动脉综合征(ACS)类型(即动脉粥样硬化性冠状动脉病变与冠状动脉非阻塞性心肌梗死[MINOCA])的独特危险因素的作用:这项研究使用了一个基于人群的队列,其中包括接受冠状动脉造影术的偶发 CAD 女性患者和年龄匹配的对照受试者。SYNTAX(TAXUS[Boston Scientific]PCI[经皮冠状动脉介入治疗]与心脏手术之间的协同作用)评分用于确定CAD的复杂性和程度;MINOCA的诊断条件是在无阻塞性冠状动脉疾病的情况下出现临床急性心肌梗死:2002年11月7日至2016年12月31日期间,共有506名明尼苏达州奥姆斯特德县(Olmsted County)准女性居民发生了CAD和血管造影数据。与血压正常的女性相比,患有高密度脂蛋白血症的女性在发病时更年轻(中位数:64.8岁 vs 71.8岁;P = 0.030)。HDP 与 ACS 之间存在密切联系(未调整 P = 0.018)。与血压正常的孕妇相比,患有HDP的孕妇更有可能具有较高的SYNTAX评分(OR:2.28;95% CI:1.02-5.12;P = 0.046)和MINOCA评分(OR:2.08;95% CI:1.02-4.25;P = 0.044):结论:HDP 史与早年的 CAD 以及未来冠状动脉阻塞性和非阻塞性心肌梗死的风险有关。这项研究强调,除了传统的风险因素外,还需要及时发现和治疗非阻塞性疾病。
{"title":"Hypertensive Disorders of Pregnancy Increase the Risk for Myocardial Infarction: A Population-Based Study.","authors":"Lisa E Vaughan, Yoshihisa Kanaji, Sonja Suvakov, Santosh Parashuram, Yvonne S Butler Tobah, Alanna M Chamberlain, Suzette J Bielinski, Natasa Milic, Rajiv Gulati, Karl A Nath, Amir Lerman, Vesna D Garovic","doi":"10.1016/j.jacc.2024.06.049","DOIUrl":"10.1016/j.jacc.2024.06.049","url":null,"abstract":"<p><strong>Background: </strong>Angiographic evidence of the anatomy of coronary arteries and the type of coronary artery lesions in women with a history of hypertensive disorders of pregnancy (HDP) are poorly documented.</p><p><strong>Objectives: </strong>This study sought to determine the role of a history of HDP as a unique risk factor for early coronary artery disease (CAD) and type of acute coronary syndrome (ACS) (ie, atherosclerotic vs myocardial infarction with nonobstructive coronary arteries [MINOCA]) in women who underwent coronary angiography.</p><p><strong>Methods: </strong>This study used a population-based cohort of parous female patients with incident CAD who underwent coronary angiography and age-matched control subjects. The SYNTAX (Synergy between PCI [percutaneous coronary intervention] with TAXUS [Boston Scientific] and Cardiac Surgery) score was assessed to determine the complexity and degree of CAD; MINOCA was diagnosed in the presence of clinical acute myocardial infarction in the absence of obstructive coronary disease.</p><p><strong>Results: </strong>A total of 506 parous female Olmsted County, Minnesota (USA) residents had incident CAD and angiographic data from November 7, 2002 to December 31, 2016. Women with HDP were younger than normotensive women at the time of the event (median: 64.8 years vs 71.8 years; P = 0.030). There was a strong association between HDP and ACS (unadjusted P = 0.018). Women with HDP compared with women with normotensive pregnancies were more likely to have a higher SYNTAX score (OR: 2.28; 95% CI: 1.02-5.12; P = 0.046), and MINOCA (OR: 2.08; 95% CI: 1.02-4.25; P = 0.044).</p><p><strong>Conclusions: </strong>A history of HDP is associated with CAD earlier in life and with a future risk for myocardial infarction with both obstructive and nonobstructive coronary arteries. This study underscores the need for timely detection and treatment of nonobstructive disease, in addition to traditional risk factors.</p>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":21.7,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Classification of Myocardial Infarction in Women With Hypertensive Disorders of Pregnancy. 妊娠高血压妇女心肌梗塞的分类。
IF 21.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-11-01 DOI: 10.1016/j.jacc.2024.07.058
Michael C Honigberg
{"title":"Classification of Myocardial Infarction in Women With Hypertensive Disorders of Pregnancy.","authors":"Michael C Honigberg","doi":"10.1016/j.jacc.2024.07.058","DOIUrl":"10.1016/j.jacc.2024.07.058","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":21.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Prognosis: The Vital Role of Quality of Life after Transcatheter Tricuspid Valve Replacement 超越预后:经导管三尖瓣置换术后生活质量的重要作用
IF 24 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1016/j.jacc.2024.10.087
Domenico Angellotti, Fabien Praz, Stephan Windecker
No Abstract
无摘要
{"title":"Beyond Prognosis: The Vital Role of Quality of Life after Transcatheter Tricuspid Valve Replacement","authors":"Domenico Angellotti, Fabien Praz, Stephan Windecker","doi":"10.1016/j.jacc.2024.10.087","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.087","url":null,"abstract":"No Abstract","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":24.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial 经导管三尖瓣置换术后的生活质量:TRISCEND II 关键性试验的 1 年结果
IF 24 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1016/j.jacc.2024.10.067
Suzanne V. Arnold, Rebecca T. Hahn, Vinod H. Thourani, Raj Makkar, Moody Makar, Rahul P. Sharma, Christiane Haeffele, Charles J. Davidson, Akhil Narang, Brian O’Neill, James Lee, Pradeep Yadav, Firas Zahr, Scott Chadderdon, Mackram Eleid, Sorin Pislaru, Robert Smith, Molly Szerlip, Brian Whisenant, Nishant Sekaran, David J. Cohen

Background

Severe tricuspid regurgitation (TR) often causes substantial impairment in patient-reported health status (ie, symptoms, physical and social function, and quality of life), which may improve with transcatheter tricuspid valve replacement (TTVR).

Objectives

We performed an in-depth analysis of health status of patients enrolled in the TRISCEND (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device) II pivotal trial to help quantify the benefit of intervention to patients.

Methods

The TRISCEND II pivotal trial randomized 400 patients with symptomatic and severe or greater TR 2:1 to TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT) or OMT alone. Health status was assessed with the Kansas City Cardiomyopathy Questionnaire and the 36-Item Short Form Health Survey. Changes in health status over 1 year were compared between treatment groups using mixed-effects repeated-measures models.

Results

The analysis cohort included 392 patients, of whom 259 underwent attempted TTVR and 133 received OMT alone (mean age 79.2 ± 7.6 years, 75.5% women, 56.1% with massive or torrential TR). Patients had substantially impaired health status at baseline (mean Kansas City Cardiomyopathy Questionnaire Overall Summary Score [KCCQ-OS] 52.1 ± 22.8; mean 36-Item Short Form Health Survey physical component summary score 35.2 ± 8.4). TTVR+OMT patients reported significantly greater improvement in both disease-specific and generic health status at each follow-up time point. Mean between-group differences in the KCCQ-OS favored TTVR+OMT at each time point: 11.8 points (95% CI: 7.4-16.3 points) at 30 days, 20.8 points (95% CI: 16.1-25.5 points) at 6 months, and 17.8 points (95% CI: 13.0-22.5 points) at 1 year. In subgroup analyses, TTVR+OMT improved health status to a greater extent among patients with torrential or massive TR vs severe TR (treatment effect 23.3 vs 22.6 vs 11.3; interaction P = 0.049). At 1 year, 64.6% of TTVR+OMT patients were alive and well (KCCQ-OS ≥60 points and no decline of ≥10 points from baseline) compared with 31.0% with OMT alone.

Conclusions

Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients’ symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device]; NCT04482062)
背景严重三尖瓣反流(TR)通常会导致患者报告的健康状况(即症状、身体和社会功能以及生活质量)严重受损,而经导管三尖瓣置换术(TTVR)可能会改善患者的健康状况:方法TRISCEND II关键性试验将400名无症状和严重或大于TR 2:1的患者随机分为使用EVOQUE三尖瓣置换系统加最佳药物治疗(OMT)或仅使用OMT进行TTVR。健康状况通过堪萨斯城心肌病问卷和 36 项简表健康调查进行评估。使用混合效应重复测量模型比较了不同治疗组一年内的健康状况变化。结果分析队列包括392名患者,其中259人接受了尝试性TTVR,133人只接受了OMT(平均年龄79.2±7.6岁,75.5%为女性,56.1%患有大面积或暴发性TR)。基线时,患者的健康状况严重受损(堪萨斯城心肌病问卷总体总分[KCCQ-OS]平均值为(52.1 ± 22.8);36项简表健康调查体格部分总分平均值为(35.2 ± 8.4)。在每个随访时间点,TTVR+OMT患者的疾病特异性和一般健康状况都有明显改善。各时间点的 KCCQ-OS 组间平均差异有利于 TTVR+OMT:30 天时为 11.8 分(95% CI:7.4-16.3 分),6 个月时为 20.8 分(95% CI:16.1-25.5 分),1 年时为 17.8 分(95% CI:13.0-22.5 分)。在亚组分析中,TTVR+OMT能在更大程度上改善暴发性或大面积TR患者与重度TR患者的健康状况(治疗效果23.3 vs 22.6 vs 11.3;交互作用P = 0.049)。1年后,64.6%的TTVR+OMT患者存活良好(KCCQ-OS≥60分,且与基线相比无≥10分的下降),而仅接受OMT治疗的患者存活良好率为31.0%。这些益处在 TTVR 治疗后 30 天就显现出来,6 个月后继续增加,1 年后仍然持续。(TRISCEND II 关键性试验[Edwards EVOQUE 经导管三尖瓣置换术:使用新型设备的安全性和临床疗效的关键临床研究];NCT04482062)
{"title":"Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial","authors":"Suzanne V. Arnold, Rebecca T. Hahn, Vinod H. Thourani, Raj Makkar, Moody Makar, Rahul P. Sharma, Christiane Haeffele, Charles J. Davidson, Akhil Narang, Brian O’Neill, James Lee, Pradeep Yadav, Firas Zahr, Scott Chadderdon, Mackram Eleid, Sorin Pislaru, Robert Smith, Molly Szerlip, Brian Whisenant, Nishant Sekaran, David J. Cohen","doi":"10.1016/j.jacc.2024.10.067","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.067","url":null,"abstract":"<h3>Background</h3>Severe tricuspid regurgitation (TR) often causes substantial impairment in patient-reported health status (ie, symptoms, physical and social function, and quality of life), which may improve with transcatheter tricuspid valve replacement (TTVR).<h3>Objectives</h3>We performed an in-depth analysis of health status of patients enrolled in the TRISCEND (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device) II pivotal trial to help quantify the benefit of intervention to patients.<h3>Methods</h3>The TRISCEND II pivotal trial randomized 400 patients with symptomatic and severe or greater TR 2:1 to TTVR with the EVOQUE tricuspid valve replacement system plus optimal medical therapy (OMT) or OMT alone. Health status was assessed with the Kansas City Cardiomyopathy Questionnaire and the 36-Item Short Form Health Survey. Changes in health status over 1 year were compared between treatment groups using mixed-effects repeated-measures models.<h3>Results</h3>The analysis cohort included 392 patients, of whom 259 underwent attempted TTVR and 133 received OMT alone (mean age 79.2 ± 7.6 years, 75.5% women, 56.1% with massive or torrential TR). Patients had substantially impaired health status at baseline (mean Kansas City Cardiomyopathy Questionnaire Overall Summary Score [KCCQ-OS] 52.1 ± 22.8; mean 36-Item Short Form Health Survey physical component summary score 35.2 ± 8.4). TTVR+OMT patients reported significantly greater improvement in both disease-specific and generic health status at each follow-up time point. Mean between-group differences in the KCCQ-OS favored TTVR+OMT at each time point: 11.8 points (95% CI: 7.4-16.3 points) at 30 days, 20.8 points (95% CI: 16.1-25.5 points) at 6 months, and 17.8 points (95% CI: 13.0-22.5 points) at 1 year. In subgroup analyses, TTVR+OMT improved health status to a greater extent among patients with torrential or massive TR vs severe TR (treatment effect 23.3 vs 22.6 vs 11.3; interaction <em>P</em> = 0.049). At 1 year, 64.6% of TTVR+OMT patients were alive and well (KCCQ-OS ≥60 points and no decline of ≥10 points from baseline) compared with 31.0% with OMT alone.<h3>Conclusions</h3>Compared with OMT alone, treatment of patients with symptomatic and severe or greater TR with TTVR+OMT resulted in substantial improvement in patients’ symptoms, function, and quality of life. These benefits were evident 30 days after TTVR, continued to increase through 6 months, and remained durable through 1 year. (TRISCEND II Pivotal Trial [Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy using a Novel Device]; <span><span>NCT04482062</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>)","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":24.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial 新型低剂量西罗莫司洗脱生物可降解聚合物支架与第二代 DES 的随机比较:TARGET-IV NA 试验
IF 24 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1016/j.jacc.2024.10.074
Robert W. Yeh, Olivier F. Bertrand, Ehtisham Mahmud, Emanuele Barbato, Batla Falah, Melek Ozgu Issever, Björn Redfors, Alexandra Popma, Michael Curtis, Niels van Royen, Jean-Francois Tanguay, Luc Janssens, William N. Newman, Koen Teeuwen, James W. Choi, Maurits T. Dirksen, Akiko Maehara, Martin B. Leon
<h3>Background</h3>Drug-eluting stents (DESs) with controlled antiproliferative drug release reduce restenosis risk, but durable polymers can delay healing and inhibit reendothelialization. The Firehawk biodegradable polymer sirolimus-eluting stent (BP-SES) has a fully biodegradable sirolimus-containing polymer coating localized to recessed abluminal grooves on the stent surface and delivers roughly one-third the drug dose of other DESs.<h3>Objectives</h3>We report the primary results of the TARGET-IV NA (Firehawk Rapamycin Target Eluting Coronary Stent North American Trial) randomized controlled trial comparing clinical outcomes with BP-SES vs currently used second-generation DESs.<h3>Methods</h3>The TARGET-IV NA study was a prospective, multicenter, single-blind, 1:1 randomized noninferiority trial comparing the BP-SES with control in North America and Europe among patients undergoing percutaneous coronary intervention for chronic or acute coronary syndromes. The primary endpoint was target lesion failure (TLF) at 12 months (composite of cardiac death, target vessel–related myocardial infarction, or ischemia-driven target lesion revascularization). The primary analysis (intention-to-treat) tested noninferiority of BP-SES vs control using an absolute margin of 3.85% and 1-sided α of 0.025. Noninferiority-powered secondary endpoints were tested in an optical coherence tomography substudy (endpoint: mean neointimal hyperplasia thickness) and an angiography substudy (endpoint: in-stent late lumen loss).<h3>Results</h3>A total of 1,720 patients (mean age 66 years; 74% male) with 2,159 lesions were randomly allocated to receive either BP-SES (860 patients, 1,057 lesions) or control second-generation DES (860 patients, 1,084 lesions). A total of 61% of patients presented with stable coronary disease, 32% had unstable angina, and 7% had non-ST-segment elevation myocardial infarction (NSTEMI) or recent ST-segment elevation myocardial infarction. The rate of TLF with BP-SES was noninferior to control at 12 months (3.4% vs 3.3%, absolute risk difference 0.13%, upper bound 97.5% CI: 2.03, <em>P</em><sub>noninferiority</sub> < 0.0001). Cardiac death, myocardial infarction, and stent thrombosis rates were similar between groups. Angiographic follow-up was available in 104 patients (97.2% of those enrolled in the angiographic substudy) and 128 (94.1%) lesions. At 13 months, the powered secondary endpoint of mean in-stent late lumen loss was 0.149 ± 0.263 mm for BP-SES and 0.327 ± 0.463 mm for control (least squares mean difference: −0.178; 90% CI: −0.2943 to −0.0632; <em>P</em><sub>noninferiority</sub> < 0.0001). The optical coherence tomography substudy included 37 patients (42 lesions) with no difference in mean neointimal hyperplasia thickness between groups at 13 months (<em>P</em><sub>noninferiority</sub> = 0.01).<h3>Conclusions</h3>The biodegradable polymer sirolimus-eluting stent was noninferior to currently used second-generation DES with regard
背景药物洗脱支架(DES)具有可控的抗增殖药物释放功能,可降低再狭窄风险,但耐久性聚合物会延迟愈合并抑制再内皮化。我们报告了TARGET-IV NA(Firehawk Rapamycin靶向洗脱冠状动脉支架北美试验)随机对照试验的主要结果,该试验比较了BP-SES与目前使用的第二代DES的临床效果。方法TARGET-IV NA 研究是一项前瞻性、多中心、单盲、1:1 随机非劣效性试验,在北美和欧洲接受经皮冠状动脉介入治疗的慢性或急性冠状动脉综合征患者中比较 BP-SES 与对照组。主要终点是 12 个月时的靶病变失败 (TLF)(心源性死亡、靶血管相关心肌梗死或缺血驱动的靶病变血运重建的综合结果)。主要分析(意向治疗)检验了 BP-SES 与对照组的非劣效性,绝对差值为 3.85%,单侧 α 为 0.025。在光学相干断层扫描子研究(终点:平均新血管增生厚度)和血管造影子研究(终点:支架内晚期管腔损失)中对非劣效性次要终点进行了测试。结果 共有1720名患者(平均年龄66岁;74%为男性)的2159个病变被随机分配到BP-SES(860名患者,1057个病变)或对照组第二代DES(860名患者,1084个病变)。61%的患者冠状动脉疾病稳定,32%的患者心绞痛不稳定,7%的患者患有非ST段抬高型心肌梗死(NSTEMI)或近期ST段抬高型心肌梗死。12 个月时,BP-SES 的 TLF 发生率不劣于对照组(3.4% vs 3.3%,绝对风险差异 0.13%,上限 97.5% CI:2.03,Pnoninferiority < 0.0001)。两组的心源性死亡、心肌梗死和支架血栓形成率相似。104名患者(占血管造影子研究入选者的97.2%)和128个病灶(94.1%)接受了血管造影随访。13 个月后,BP-SES 的次要终点平均支架内晚期管腔损失为 0.149 ± 0.263 mm,对照组为 0.327 ± 0.463 mm(最小二乘法平均差:-0.178;90%):-0.178;90% CI:-0.2943 至 -0.0632;Pnoninferiority < 0.0001)。结论可降解聚合物西罗莫司洗脱支架1年后的TLF不劣于目前使用的第二代DES。(Firehawk® Rapamycin靶向洗脱冠状动脉支架北美试验;NCT04562532)。
{"title":"Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial","authors":"Robert W. Yeh, Olivier F. Bertrand, Ehtisham Mahmud, Emanuele Barbato, Batla Falah, Melek Ozgu Issever, Björn Redfors, Alexandra Popma, Michael Curtis, Niels van Royen, Jean-Francois Tanguay, Luc Janssens, William N. Newman, Koen Teeuwen, James W. Choi, Maurits T. Dirksen, Akiko Maehara, Martin B. Leon","doi":"10.1016/j.jacc.2024.10.074","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.074","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Drug-eluting stents (DESs) with controlled antiproliferative drug release reduce restenosis risk, but durable polymers can delay healing and inhibit reendothelialization. The Firehawk biodegradable polymer sirolimus-eluting stent (BP-SES) has a fully biodegradable sirolimus-containing polymer coating localized to recessed abluminal grooves on the stent surface and delivers roughly one-third the drug dose of other DESs.&lt;h3&gt;Objectives&lt;/h3&gt;We report the primary results of the TARGET-IV NA (Firehawk Rapamycin Target Eluting Coronary Stent North American Trial) randomized controlled trial comparing clinical outcomes with BP-SES vs currently used second-generation DESs.&lt;h3&gt;Methods&lt;/h3&gt;The TARGET-IV NA study was a prospective, multicenter, single-blind, 1:1 randomized noninferiority trial comparing the BP-SES with control in North America and Europe among patients undergoing percutaneous coronary intervention for chronic or acute coronary syndromes. The primary endpoint was target lesion failure (TLF) at 12 months (composite of cardiac death, target vessel–related myocardial infarction, or ischemia-driven target lesion revascularization). The primary analysis (intention-to-treat) tested noninferiority of BP-SES vs control using an absolute margin of 3.85% and 1-sided α of 0.025. Noninferiority-powered secondary endpoints were tested in an optical coherence tomography substudy (endpoint: mean neointimal hyperplasia thickness) and an angiography substudy (endpoint: in-stent late lumen loss).&lt;h3&gt;Results&lt;/h3&gt;A total of 1,720 patients (mean age 66 years; 74% male) with 2,159 lesions were randomly allocated to receive either BP-SES (860 patients, 1,057 lesions) or control second-generation DES (860 patients, 1,084 lesions). A total of 61% of patients presented with stable coronary disease, 32% had unstable angina, and 7% had non-ST-segment elevation myocardial infarction (NSTEMI) or recent ST-segment elevation myocardial infarction. The rate of TLF with BP-SES was noninferior to control at 12 months (3.4% vs 3.3%, absolute risk difference 0.13%, upper bound 97.5% CI: 2.03, &lt;em&gt;P&lt;/em&gt;&lt;sub&gt;noninferiority&lt;/sub&gt; &lt; 0.0001). Cardiac death, myocardial infarction, and stent thrombosis rates were similar between groups. Angiographic follow-up was available in 104 patients (97.2% of those enrolled in the angiographic substudy) and 128 (94.1%) lesions. At 13 months, the powered secondary endpoint of mean in-stent late lumen loss was 0.149 ± 0.263 mm for BP-SES and 0.327 ± 0.463 mm for control (least squares mean difference: −0.178; 90% CI: −0.2943 to −0.0632; &lt;em&gt;P&lt;/em&gt;&lt;sub&gt;noninferiority&lt;/sub&gt; &lt; 0.0001). The optical coherence tomography substudy included 37 patients (42 lesions) with no difference in mean neointimal hyperplasia thickness between groups at 13 months (&lt;em&gt;P&lt;/em&gt;&lt;sub&gt;noninferiority&lt;/sub&gt; = 0.01).&lt;h3&gt;Conclusions&lt;/h3&gt;The biodegradable polymer sirolimus-eluting stent was noninferior to currently used second-generation DES with regard","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":24.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcatheter Interventions in Tricuspid Regurgitation: Shifting the focus beyond Quantity of Life to Quality of Life 三尖瓣反流的经导管介入治疗:将重点从 "生活数量 "转移到 "生活质量 "上来
IF 24 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1016/j.jacc.2024.10.085
Aakriti Gupta, Celina Yong, Rasha Al-Lamee
No Abstract
无摘要
{"title":"Transcatheter Interventions in Tricuspid Regurgitation: Shifting the focus beyond Quantity of Life to Quality of Life","authors":"Aakriti Gupta, Celina Yong, Rasha Al-Lamee","doi":"10.1016/j.jacc.2024.10.085","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.085","url":null,"abstract":"No Abstract","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":24.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in Transcatheter Tricuspid Valve Interventions—Implications for Health Policy 经导管三尖瓣介入疗法的进展--对卫生政策的影响
IF 24 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 DOI: 10.1016/j.jacc.2024.10.089
Kushal T. Kadakia, Sanket S. Dhruva
No Abstract
无摘要
{"title":"Advances in Transcatheter Tricuspid Valve Interventions—Implications for Health Policy","authors":"Kushal T. Kadakia, Sanket S. Dhruva","doi":"10.1016/j.jacc.2024.10.089","DOIUrl":"https://doi.org/10.1016/j.jacc.2024.10.089","url":null,"abstract":"No Abstract","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":24.0,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TCT-229 Rebound Phenomenon of Platelet Reactivity After Cessation of Long-term Clopidogrel Therapy TCT-229 停止长期氯吡格雷治疗后血小板反应性的反弹现象
IF 21.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 DOI: 10.1016/j.jacc.2024.09.265
{"title":"TCT-229 Rebound Phenomenon of Platelet Reactivity After Cessation of Long-term Clopidogrel Therapy","authors":"","doi":"10.1016/j.jacc.2024.09.265","DOIUrl":"10.1016/j.jacc.2024.09.265","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":21.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TCT-244 Prevalence of Cardiovascular Outcomes in Patients With Tetralogy of Fallot: A Nationwide Inpatient Analysis TCT-244 法洛氏四联症患者的心血管预后:全国住院患者分析
IF 21.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-29 DOI: 10.1016/j.jacc.2024.09.285
{"title":"TCT-244 Prevalence of Cardiovascular Outcomes in Patients With Tetralogy of Fallot: A Nationwide Inpatient Analysis","authors":"","doi":"10.1016/j.jacc.2024.09.285","DOIUrl":"10.1016/j.jacc.2024.09.285","url":null,"abstract":"","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":null,"pages":null},"PeriodicalIF":21.7,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142532239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the American College of Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1